- 17:00Israel vows to strike Iran again if threatened, defense minister warns
- 16:20Morocco sees record 8.9 million tourists in first half of 2025
- 15:50Morocco aims to secure five-month wheat stock amid price drop
- 15:20Macron and Starmer to sign historic nuclear deterrence pact
- 14:50Chemsedine Talbi completes Sunderland move after stellar Club Brugge season
- 14:20Police in Marrakech detain Algerian-French suspect wanted by Interpol
- 13:30EU unveils stockpiling plan to prepare for crises and conflict
- 12:50Spain eases lockdowns as firefighters stabilize Catalonia forest blaze
- 12:20Spaniards favor China over the US in shifting global perceptions
Follow us on Facebook
AstraZeneca Withdraws Vaxzevria, Its Pioneering COVID-19 Vaccine
In a pivotal move marking the end of an era, British pharmaceutical giant AstraZeneca has announced the withdrawal of its trailblazing COVID-19 vaccine, Vaxzevria, from the global market, citing commercial reasons. Once hailed as a game-changer during the pandemic's early days, the vaccine's demise reflects the rapidly evolving landscape of the fight against the virus.
According to AstraZeneca's statement, the decision to discontinue sales of Vaxzevria was driven by the proliferation of updated COVID-19 vaccines tailored to combat emerging variants, leading to a surplus and subsequent decline in demand for their initial offering. "With multiple updated COVID-19 vaccines now available, there is an oversupply," the company explained, justifying the withdrawal of a vaccine that once held immense promise.
Vaxzevria, formerly known as the Oxford-AstraZeneca vaccine, was one of the first COVID-19 vaccines to be widely distributed during the pandemic's early stages. Its impact was profound, offering a glimmer of hope amidst the chaos and uncertainty that gripped the world. However, as the virus evolved and new variants emerged, the need for updated vaccines became paramount, ultimately relegating Vaxzevria to the annals of history.
The withdrawal of Vaxzevria from the European Union market is immediate, with AstraZeneca's decision rendering the vaccine obsolete within the bloc. However, the company's departure from the COVID-19 vaccine arena is not without controversy. In the United Kingdom, a class-action lawsuit is currently underway, alleging that the use of Vaxzevria resulted in severe harm and, in some cases, death in dozens of instances.
Moreover, reports from Belgium's Federal Agency for Medicines and Health Products (FAGG) in January 2022 indicated that two individuals had tragically lost their lives due to thrombosis with thrombocytopenia syndrome (TTS) after receiving the Janssen COVID-19 vaccine and Vaxzevria.
As the world continues to grapple with the evolving challenges of the pandemic, AstraZeneca's decision to retire Vaxzevria serves as a poignant reminder of the relentless pursuit of scientific advancement and the ever-changing nature of the battle against COVID-19. While the vaccine's impact will forever be etched in history, its withdrawal paves the way for newer, more tailored solutions to combat the virus's persistent threat.